Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin

Kajosaari, Lauri I., Laitila, Jouko, Neuvonen, Pertti J., Backman, Janne T. · 2005 · Basic & Clinical Pharmacology & Toxicology

Abstract

Repaglinide is an antidiabetic drug metabolised by cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes. To clarify the mechanisms of observed repaglinide drug interactions, we determined the contribution of the two enzymes to repaglinide metabolism at different substrate concentrations, and examined the effect of fibrates and rifampicin on CYP2C8, CYP3A4 and repaglinide metabolism in vitro. We studied repaglinide metabolism using pooled human liver microsomes, recombinant CYP2C8 and recombinant CYP3A4 enzymes. The effect of quercetin and itraconazole on repaglinide metabolism, and of gemfibrozil, bezafibrate, fenofibrate and rifampicin on CYP2C8 (paclitaxel 6α‐hydroxylation) and CYP3A4 (midazolam 1‐hydroxylation) activities and repaglinide metabolism were studied using human liver microsomes. At therapeutic repaglinide concentrations (<0.4 μM), CYP2C8 and CYP3A4 metabolised repaglinide at similar rates. Quercetin (25 μM) and itraconazole (3 μM) inhibited the metabolism of 0.2 μM repaglinide by 58% and 71%, and that of 2 μM repaglinide by 56% and 59%, respectively. The three fibrates inhibited CYP2C8 (K i: bezafibrate 9.7 μM, gemfibrozil 30.4 μM and fenofibrate 92.6 μM) and repaglinide metabolism (IC 50: bezafibrate 37.7 μM, gemfibrozil 111 μM and fenofibrate 164 μM), but had no effect on CYP3A4. Rifampicin inhibited CYP2C8 (K i 30.2 μM), CYP3A4 (K i 18.5 μM) and repaglinide metabolism (IC 50 13.7 μM). In conclusion, both CYP2C8 and CYP3A4 are important in the metabolism of therapeutic concentrations of repaglinide in vitro, but their predicted contributions in vivo are highly dependent on the scaling factor used. Gemfibrozil is only a moderate inhibitor of CYP2C8 and does not inhibit CYP3A4; inhibition of CYP‐enzymes by parent gemfibrozil alone does not explain its interaction with repaglinide in vivo. Rifampicin competitively inhibits both CYP2C8 and CYP3A4, which can counteract its inducing effect in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-7843.2005.pto_157.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 172

Metadata

Authors
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T.
Venue
Basic & Clinical Pharmacology & Toxicology
Publisher
Wiley
Published
2005-09-20
Volume
97
Issue
4
Pages
249-256
ISSN
  • 1742-7835 (ISSN-L)
  • 1742-7843
OpenAlex
W2069390464
Cited by
172
References
2
FWCI
8.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin. https://app.cochat.ai/papers/10.1111/j.1742-7843.2005.pto_157.x
The paper
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005). Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2005.pto_157.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.